BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33887686)

  • 1. Prospective experimental treatment of colorectal cancer patients based on organoid drug responses.
    Ooft SN; Weeber F; Schipper L; Dijkstra KK; McLean CM; Kaing S; van de Haar J; Prevoo W; van Werkhoven E; Snaebjornsson P; Hoes LR; Chalabi M; van der Velden D; van Leerdam M; Boot H; Grootscholten C; Huitema ADR; Bloemendal HJ; Cuppen E; Voest EE
    ESMO Open; 2021 Jun; 6(3):100103. PubMed ID: 33887686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy.
    Narasimhan V; Wright JA; Churchill M; Wang T; Rosati R; Lannagan TRM; Vrbanac L; Richardson AB; Kobayashi H; Price T; Tye GXY; Marker J; Hewett PJ; Flood MP; Pereira S; Whitney GA; Michael M; Tie J; Mukherjee S; Grandori C; Heriot AG; Worthley DL; Ramsay RG; Woods SL
    Clin Cancer Res; 2020 Jul; 26(14):3662-3670. PubMed ID: 32376656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine applied to metastatic colorectal cancer using tumor-derived organoids and in-vitro sensitivity testing: a phase 2, single-center, open-label, and non-comparative study.
    Jensen LH; Rogatto SR; Lindebjerg J; Havelund B; Abildgaard C; do Canto LM; Vagn-Hansen C; Dam C; Rafaelsen S; Hansen TF
    J Exp Clin Cancer Res; 2023 May; 42(1):115. PubMed ID: 37143108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-derived organoids as a preclinical platform for precision medicine in colorectal cancer.
    Cho YW; Min DW; Kim HP; An Y; Kim S; Youk J; Chun J; Im JP; Song SH; Ju YS; Han SW; Park KJ; Kim TY
    Mol Oncol; 2022 Jun; 16(12):2396-2412. PubMed ID: 34850547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of Using a Patient-Derived Tumor Organoid Culture Model to Predict the Response to Chemotherapy Regimens In Stage IV Colorectal Cancer: A Blinded Study.
    Wang T; Pan W; Zheng H; Zheng H; Wang Z; Li JJ; Deng C; Yan J
    Dis Colon Rectum; 2021 Jul; 64(7):833-850. PubMed ID: 33709991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer: A Systematic Review.
    Flood M; Narasimhan V; Wilson K; Lim WM; Ramsay R; Michael M; Heriot A
    Ann Surg Oncol; 2022 Jan; 29(1):47-59. PubMed ID: 34596795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
    Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
    J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective derivation of a living organoid biobank of colorectal cancer patients.
    van de Wetering M; Francies HE; Francis JM; Bounova G; Iorio F; Pronk A; van Houdt W; van Gorp J; Taylor-Weiner A; Kester L; McLaren-Douglas A; Blokker J; Jaksani S; Bartfeld S; Volckman R; van Sluis P; Li VS; Seepo S; Sekhar Pedamallu C; Cibulskis K; Carter SL; McKenna A; Lawrence MS; Lichtenstein L; Stewart C; Koster J; Versteeg R; van Oudenaarden A; Saez-Rodriguez J; Vries RG; Getz G; Wessels L; Stratton MR; McDermott U; Meyerson M; Garnett MJ; Clevers H
    Cell; 2015 May; 161(4):933-45. PubMed ID: 25957691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases.
    Weeber F; van de Wetering M; Hoogstraat M; Dijkstra KK; Krijgsman O; Kuilman T; Gadellaa-van Hooijdonk CG; van der Velden DL; Peeper DS; Cuppen EP; Vries RG; Clevers H; Voest EE
    Proc Natl Acad Sci U S A; 2015 Oct; 112(43):13308-11. PubMed ID: 26460009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
    Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
    J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the Tumor Microenvironment of Colorectal Cancer and Guiding Clinical Treatment With Patient-Derived Organoid Technology: Progress and Challenges.
    Li J; Liu J; Xia W; Yang H; Sha W; Chen H
    Technol Cancer Res Treat; 2024; 23():15330338231221856. PubMed ID: 38225190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation.
    Pasch CA; Favreau PF; Yueh AE; Babiarz CP; Gillette AA; Sharick JT; Karim MR; Nickel KP; DeZeeuw AK; Sprackling CM; Emmerich PB; DeStefanis RA; Pitera RT; Payne SN; Korkos DP; Clipson L; Walsh CM; Miller D; Carchman EH; Burkard ME; Lemmon KK; Matkowskyj KA; Newton MA; Ong IM; Bassetti MF; Kimple RJ; Skala MC; Deming DA
    Clin Cancer Res; 2019 Sep; 25(17):5376-5387. PubMed ID: 31175091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studying cellular heterogeneity and drug sensitivity in colorectal cancer using organoid technology.
    Sasaki N; Clevers H
    Curr Opin Genet Dev; 2018 Oct; 52():117-122. PubMed ID: 30261425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organoid Models of Colorectal Pathology: Do They Hold the Key to Personalized Medicine? A Systematic Review.
    DeHaan RK; Sarvestani SK; Huang EH
    Dis Colon Rectum; 2020 Nov; 63(11):1559-1569. PubMed ID: 32868555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organoid Culture of Isolated Cells from Patient-derived Tissues with Colorectal Cancer.
    Xie BY; Wu AW
    Chin Med J (Engl); 2016 Oct; 129(20):2469-2475. PubMed ID: 27748340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
    Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
    Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug screening by uniform patient derived colorectal cancer hydro-organoids.
    Jung YH; Choi DH; Park K; Lee SB; Kim J; Kim H; Jeong HW; Yang JH; Kim JA; Chung S; Min BS
    Biomaterials; 2021 Sep; 276():121004. PubMed ID: 34273688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Organoid screening reveals epigenetic vulnerabilities in human colorectal cancer.
    Toshimitsu K; Takano A; Fujii M; Togasaki K; Matano M; Takahashi S; Kanai T; Sato T
    Nat Chem Biol; 2022 Jun; 18(6):605-614. PubMed ID: 35273398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Colon Organoids and Other Laboratory Strategies to Enhance Patient Treatment Selection.
    Johnson KA; DeStefanis RA; Emmerich PB; Grogan PT; Kratz JD; Makkar SK; Clipson L; Deming DA
    Curr Treat Options Oncol; 2020 Apr; 21(5):35. PubMed ID: 32328818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.